Building a $14B Lab Business: David King on CEO Development, Decisions & Culture at Scale
Most people know LabCorp for routine blood work. But under CEO Dave King, the company expanded far beyond basic diagnostics, scaling from about $4B to $14B in revenue while navigating relentless pricing pressure, major acquisitions, and a rapidly changing healthcare landscape.
In this conversation, Dave breaks down what it really takes to scale through M&A, why some deals worked and others missed expectations, and how to lead when decisions draw criticism. He also talks about Theranos, why he stayed quiet publicly, and how the science ultimately caught up. Finally, he shares how LabCorp built a unified, patient first culture across roles ranging from PhDs to couriers and phlebotomists, and why the team’s Covid response became one of his proudest moments.
What you’ll hear in this episode:
-The economics of the lab business and why volume matters
-How Dave went from prosecutor and partner to LabCorp general counsel and then CEO
-Building real compliance culture after a corporate integrity agreement
-The biggest shift when you become CEO and why it takes time to learn the job
-The “lazy with the numbers” moment and how it reshaped his leadership
-LabCorp’s M&A strategy, including Genzyme Genetics and the Covance deal
-Theranos behind the scenes and why LabCorp avoided taking the bait publicly
-Navigating PAMA reimbursement cuts in a high fixed cost model-Succession, stepping away gracefully, and not becoming the “court of appeals”
-How to build culture across a massive, diverse workforce
-Why LabCorp’s Covid response is the moment he’s most proud of
Timestamps:
00:00:00 LabCorp’s transformation and Dave King intro
00:01:10 The scale story: CEO tenure, growth, and deal reality
00:02:06 Early life: DC, Illinois, Berkeley
00:03:10 Princeton, public affairs, Near Eastern studies
00:03:32 Teaching high school and why he chose law
00:04:40 Traditional legal career: clerk, prosecutor, big firm
00:05:53 Meeting LabCorp through investigations
00:06:31 Why he moved in house and what changed personally
00:08:15 Compliance culture shift and staffing legal and compliance
00:09:23 Becoming CEO later in life and why that helped
00:11:31 The real CEO job versus ops leadership
00:13:09 “You’re lazy with the numbers” and the habit that fixed it
00:15:54 Strategy pivot: pricing pressure and broadening the revenue base
00:18:17 Genzyme Genetics and building leadership in genetics
00:20:23 Integration philosophy: one LabCorp culture
00:22:42 Deals you do not do and what he regrets not bolstering
00:24:52 Theranos: investor distraction, science reality, and why he stayed quiet
00:30:50 The Covance deal: why it mattered and the precision medicine thesis
00:33:10 Why Covance under delivered and what he learned
00:35:13 Leadership means decisions plus criticism
00:36:03 PAMA cuts: what happens in high fixed cost economics
00:39:06 Retirement planning and timing
00:40:35 Succession and stepping away gracefully
00:43:29 Not the court of appeals: how to support the new CEO
00:44:35 Culture across roles: scientists, couriers, phlebotomists
00:48:09 Senior team stability and deliberate hiring
00:49:47 Proud moments: the Covid response and the team’s intensity
00:52:19 Closing thoughts